---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005470"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:22:25.525383+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics reports ~$514M cash; President/COO resigns, CEO assumes President role; new director appointed

## Summary
- Fariborz Kamal resigned as President/COO effective Dec 31, 2025; transitions to part-time Chief Technical Advisor.
- CEO David Kirn appointed President as of Jan 1, 2026, in addition to CEO role.
- Glenn Sblendorio appointed to Board as Class I director effective Jan 5, 2026, serving on Compensation and Science/Technology Committees.
- Preliminary cash, cash equivalents and marketable securities ~$514M as of Dec 31, 2025 (unaudited, subject to closing).
- Mr. Sblendorio received initial option for 45,000 shares at $7.30 exercise price; annual cash retainer of $40,000 plus committee fees.

## SEC filing metadata
- accession: 0001193125-26-005470
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526005470/0001193125-26-005470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526005470/fdmt-20251231.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005470
- JSON: https://secwatch.observer/filing/0001193125-26-005470.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.